Product
Ad26.RSV.preF-based Vaccine
1 clinical trial
1 indication
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSVStatus: Completed, Estimated PCD: 2022-08-12